Press release ·
Keyline raises $140M Series B
The funding supports the Phase 1 study of KL-101 and grows the design and lab platform.
CAMBRIDGE, Mass., June 3, 2026 · Keyline Bio today closed a $140 million Series B. Fernhill Life Ventures led the round, with Quarry Lane Capital and Tidewell Partners.
Keyline plans to use the funding to run the Phase 1 study of KL-101, move KL-118 and KL-204 toward the clinic, and expand its automated lab.
Forward-looking statements. This press release has forward-looking statements, such as plans for clinical studies, timing and the use of funds. They are based on what Keyline knows today and are subject to risks and uncertainties, so actual results can be different. Keyline does not have to update them. (Sample text for a demo site.)